药石科技: 关于提前赎回药石转债的第十六次提示性公告

Core Viewpoint - Nanjing PharmaBlock Technology Co., Ltd. has announced the early redemption of its convertible bonds ("PharmaBlock Convertible Bonds") due to the stock price exceeding the specified threshold, aiming to reduce financial costs and expenses [2][7]. Group 1: Convertible Bond Issuance and Redemption - The company issued 11.5 million convertible bonds at a face value of 100 RMB each, raising a total of 1.15 billion RMB on April 20, 2022 [2][3]. - The bonds are set to be redeemed at a price of 100.62 RMB per bond, which includes accrued interest calculated based on a 1.5% annual interest rate [8][9]. - The redemption was triggered as the stock price was above 130% of the conversion price for at least 15 trading days [6][7]. Group 2: Conversion Price Adjustments - The conversion price was adjusted from 92.98 RMB to 92.88 RMB after a cash dividend distribution on June 13, 2022 [3][4]. - Subsequent adjustments were made, with the conversion price being lowered to 34.20 RMB as of June 14, 2024, based on stock trading averages [4][5]. - The latest conversion price before redemption is set at 33.61 RMB per share [6]. Group 3: Redemption Process and Timeline - The redemption process includes a series of announcements leading up to the redemption date, with trading of the bonds ceasing on September 15, 2025 [9]. - The actual redemption date is September 18, 2025, with funds expected to reach bondholders' accounts by September 25, 2025 [9][10]. - The company will publish the redemption results and delisting announcement within seven trading days after the redemption [9].